The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Purpose
The Annual Charges Exemption (ACE) scheme which came into operation on 1 July 2015 provides an exemption from annual charges until a product first generates turnover. Once a product has turnover then the annual charge is payable for the relevant entry in the Australian Register of Therapeutic Goods (the Register) for that financial year and each subsequent financial year (that the good remains on the Register).
From 1 July 2015, sponsors of certain high risk therapeutic goods can seek a waiver from the annual charge (under subregulation 43AAH of the Therapeutic Goods Regulations 1990 (the Regulations) if:
- it is not financially viable for the therapeutic good to remain on the Register if the annual charge was payable and
- it is in the interest of public health for the therapeutic good to remain on the Register.
It is the responsibility of the sponsor to provide the TGA with sufficient evidence to allow a delegate to be satisfied about both those matters.
The objective of the waiver provisions in the Regulations is to ensure the continued availability of essential therapeutic goods to the Australian public. Sponsors should note that a waiver will only be approved in exceptional circumstances.
See Evidence requirements for what is considered in determining financial viability and public health interests.
Note
If you are exempt from paying the annual charge for a financial year under the ACE scheme, then there is no need to apply for a waiver for that financial year.
Under the ACE scheme, newly registered or included goods in the Register are automatically exempt from paying the annual charge until they commence turnover.